Healx
Cambridge, England, United Kingdom · Artificial Intelligence, Biotechnology, Health Care
Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet disco
Key facts
- Headquarters
- Cambridge, England, United Kingdom
- Employees
- 72
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- healx.ai
- Company page
Recent activity at Healx
Healx funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2024 | Series C | $47.0M |
Leadership
- Joseph Fernandes, Executive Officer
- Nhi Nguyen, Executive Officer
- Finally Fund Admin LLC, Director
- Nathan Brown, Director
- Tim Guilliams, Chief Executive Officer
- Joseph Fernandes, Executive Officer
- Nhi Nguyen, Executive Officer
- Finally Fund Admin LLC, Director
- Joseph Fernandes, Executive Officer
- Nhi Nguyen, Executive Officer
- Finally Fund Admin LLC, Director
Verified email and direct lines for Healx’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Healx in the news
- Healx Announces First Patient Dosed in Phase 1/2 Trial to - GlobeNewswire (Jul 22, 2026)
- Healx: AI-driven drug repurposing for rare disease - Pharmaceutical Technology (Jul 22, 2021)
- Artificial intelligence in drug repurposing for rare diseases: a mini-review - Frontiers (Jun 25, 2024)
- Healx AI alliance with US-based Vuja De Sciences targets killer cancer recurrence - Business Weekly (Sep 22, 2025)
- Boehringer Ingelheim pairs with AI firm Healx to repurpose assets for rare neurological disorders - Fierce Biotech (Dec 09, 2019)
- $40m 'Superman' backed fund partners with Healx to fight paralysis - Business Weekly (Jun 30, 2025)
- Healx raises $47m Series C to progress AI-driven rare disease solution - Business Weekly (Jul 31, 2024)
- History beckons as Healx doses first rare cancer patient with AI-created drug - Business Weekly (Feb 23, 2025)
Companies similar to Healx
- BPGbio · Artificial Intelligence, Biotechnology, Health Care, Therapeutics
- Neurogene · Biotechnology, Health Care, Other, Therapeutics
- Panther Life Sciences · Artificial Intelligence, Biotechnology, Health Care, Therapeutics
- Newronika · Artificial Intelligence, Biotechnology, Health Care, Therapeutics
- FYR · Artificial Intelligence, Biotechnology, Health Care, Therapeutics
About Healx: questions and answers
What does Healx do?
Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet disco
Where is Healx headquartered?
Healx is headquartered in Cambridge, England, United Kingdom.
How many employees does Healx have?
Healx has about 72 employees.
Has Healx raised funding?
Yes. Fundz has recorded 1 funding event for Healx. The most recent, Series C of $47.0M, was in Aug 2024.
Who leads Healx?
Tim Guilliams is a Chief Executive Officer at Healx.
What is the latest news on Healx?
On Nov 13, 2024, Healx partners with Sanofi to identify new rare disease indications for compound using AI drug discovery platform
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy